- Home
- DBVT vs AQST Comparison
DBVT vs AQST Comparison
Compare DBVT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- AQST
- Stock Information
- Founded
- DBVT 2002
- AQST 2004
- Country
- DBVT France
- AQST United States
- Employees
- DBVT N/A
- AQST N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- DBVT Health Care
- AQST Health Care
- Exchange
- DBVT Nasdaq
- AQST Nasdaq
- Market Cap
- DBVT 239.9M
- AQST 272.9M
- IPO Year
- DBVT N/A
- AQST 2018
- Fundamental
- Price
- DBVT $8.35
- AQST $2.71
- Analyst Decision
- DBVT Buy
- AQST Strong Buy
- Analyst Count
- DBVT 4
- AQST 5
- Target Price
- DBVT $14.81
- AQST $11.40
- AVG Volume (30 Days)
- DBVT 102.2K
- AQST 1.7M
- Earning Date
- DBVT 07-29-2025
- AQST 05-12-2025
- Dividend Yield
- DBVT N/A
- AQST N/A
- EPS Growth
- DBVT N/A
- AQST N/A
- EPS
- DBVT N/A
- AQST N/A
- Revenue
- DBVT $3,497,000.00
- AQST $54,228,000.00
- Revenue This Year
- DBVT $1,700.53
- AQST N/A
- Revenue Next Year
- DBVT $535.67
- AQST $40.62
- P/E Ratio
- DBVT N/A
- AQST N/A
- Revenue Growth
- DBVT N/A
- AQST 5.29
- 52 Week Low
- DBVT $2.21
- AQST $2.12
- 52 Week High
- DBVT $12.78
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- DBVT 42.98
- AQST 54.01
- Support Level
- DBVT $8.33
- AQST $2.22
- Resistance Level
- DBVT $9.92
- AQST $2.79
- Average True Range (ATR)
- DBVT 0.92
- AQST 0.19
- MACD
- DBVT -0.32
- AQST 0.04
- Stochastic Oscillator
- DBVT 4.53
- AQST 75.64
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.